Fujirebio Sues Quanterix to Protect Alzheimer’s Test Rollout (1)

Fujirebio Diagnostics Inc., developer of the first FDA-approved blood test for Alzheimer’s disease, filed a lawsuit seeking a federal court’s ruling that its test doesn’t violate a Quanterix Corp. patent, aiming to clear the way for a US launch planned for late June.

Fujirebio, a unit of Japan’s H.U. Group Holdings Inc., seeks a judgment that its Lumipulse plasma assay doesn’t infringe Quanterix’s US Patent No. 11,275,092, which covers methods for detecting tau protein in blood, according to a complaint docketed May 29 in the US District Court for the District of Delaware. Bloomberg Law estimates the patent will ...